skip to main content
Language:
Search Limited to: Search Limited to: Resource type Show Results with: Show Results with: Search type Index

A Case Control Study to Evaluate the Impact of Colchicine on Patients Admitted to the Hospital with Moderate to Severe COVID-19 Infection

The Canadian journal of infectious diseases & medical microbiology, 2020, Vol.2020, p.8865954-9 [Peer Reviewed Journal]

Copyright © 2020 Tegveer Sandhu et al. ;Copyright © 2020 Tegveer Sandhu et al. This is an open access article distributed under the Creative Commons Attribution License (the “License”), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. https://creativecommons.org/licenses/by/4.0 ;Copyright © 2020 Tegveer Sandhu et al. 2020 ;ISSN: 1712-9532 ;EISSN: 1918-1493 ;DOI: 10.1155/2020/8865954 ;PMID: 33133323

Full text available

Citations Cited by
  • Title:
    A Case Control Study to Evaluate the Impact of Colchicine on Patients Admitted to the Hospital with Moderate to Severe COVID-19 Infection
  • Author: Sandhu, Tegveer ; Tieng, Arlene ; Chilimuri, Sridhar ; Franchin, Giovanni
  • Hoepelman, Aim ; Aim Hoepelman
  • Subjects: Age ; Arthritis ; C-reactive protein ; Cardiovascular disease ; Chronic obstructive pulmonary disease ; Clinical trials ; Colchicine ; Coronaviruses ; COVID-19 ; Cytokines ; Dimers ; Disease transmission ; Drug dosages ; Expected values ; Ferritin ; Flooring ; Hospitals ; Infectious diseases ; Inflammation ; L-Lactate dehydrogenase ; Lactate dehydrogenase ; Lactic acid ; Markers ; Mortality ; Oxygen saturation ; Patients ; Pericarditis ; Renal failure ; Severe acute respiratory syndrome coronavirus 2 ; Statistical analysis ; Viral diseases ; Vital signs
  • Is Part Of: The Canadian journal of infectious diseases & medical microbiology, 2020, Vol.2020, p.8865954-9
  • Description: Background. Colchicine has been used in conditions such as periodic febrile illness, acute pericarditis, and gouty arthritis, all having a common hyperinflammatory response as seen in moderate to severe forms of coronavirus disease 2019 (COVID-19). This project was carried out during the rapid surge of cases in New York City, and the goal was to assess the efficacy of colchicine in treating patients with COVID-19. Methods. Patients admitted to two distinct pulmonary oriented floors of the BronxCare Hospital Center were compared. Patients on one floor were given colchicine in addition to standard of care, while control patients from another floor received only standard of care. Patients who had at least two separate timepoint measurements for at least two out of four serum inflammatory markers (C-reactive protein (CRP), D-dimer, ferritin, or lactate dehydrogenase (LDH)) were selected for the final comprehensive analysis. Results. An initial analysis performed on all patients, irrespective of the availability of two timepoint inflammatory markers, revealed a lower mortality (49.1% versus 72.9%, P=0.002), a lower percentage of intubations (52.8% versus 73.6%, P=0.006), and a higher discharge rate (50.9% versus 27.1%, P=0.002), in the patients who received colchicine. Patients in the final comprehensive analysis groups (34 in the colchicine group and 78 in the control group) had a similar prevalence of comorbid medical conditions, except for renal failure, which was higher in the control group (65.3% versus 35.2%, P=0.015). HTN (71.8% versus 52.9%, P=0.053) and DM (51.3% versus 32.4%, P=0.064) were also more prevalent in the control group, although the difference was not statistically significant. Patients who received colchicine had a lower mortality than the control group (47.1% versus 80.8%, P=0.0003), lower rate of intubations (47.1% versus 87.2%, P<0.0001), and a higher discharge rate (52.9% versus 19.2%, P=0.0003). Patients in the colchicine group also showed a more significant decrease in inflammatory markers for D-dimer (P=0.037), CRP (P=0.014), and ferritin (P=0.012). Conclusions. Our study demonstrates that colchicine improved outcomes in patients with COVID-19 receiving standard of care therapy. Future randomized, placebo-controlled clinical trials to assess the potential benefit of colchicine in COVID-19 are warranted.
  • Publisher: Egypt: Hindawi
  • Language: English;French
  • Identifier: ISSN: 1712-9532
    EISSN: 1918-1493
    DOI: 10.1155/2020/8865954
    PMID: 33133323
  • Source: Freely Accessible Journals
    AUTh Library subscriptions: ProQuest Central
    PubMed Central
    Directory of Open Access Journals
    Coronavirus Research Database
Back to results list
INSPIRE LIBRARY - TON DUC THANG UNIVERSITY (84-028) 37 755 057 Feedback
19 Nguyen Huu Tho St. Dist.7, HCM thuvien@tdtu.edu.vn

Copyright © 2017 INSPIRE LIBRARY - TON DUC THANG UNIVERSITY

Searching Remote Databases, Please Wait